What the Biggest ASCO Cancer Research Updates Could Mean for Patients

Each year, the American Society of Clinical Oncology Annual Meeting brings together cancer specialists from around the world to share the research most likely to shape the next chapter of cancer care. This year’s major updates point to several important themes: more precise treatment, smarter use of surgery and chemotherapy, new approaches for difficult-to-treat cancers and a growing recognition that supportive care, including exercise, can be part of cancer treatment planning.

By
June 8, 2026
10 min

Baptist Health South Florida

Objective:

To summarize key cancer research updates presented at the American Society of Clinical Oncology Annual Meeting.

Key Findings:

Daraxonrasib nearly doubled median overall survival in metastatic pancreatic cancer.
Ivonescimab improved overall survival in advanced squamous non-small cell lung cancer.
Selpercatinib may reduce recurrence risk in early-stage RET fusion-positive lung cancer.
Adding apalutamide to therapy improved outcomes in high-risk localized prostate cancer.
Pembrolizumab combined with chemotherapy led to better long-term survival in triple-negative breast cancer.

Interpretation:

Limitations:

Many treatments discussed are still investigational and not yet approved for general use.
Further studies are needed to compare new treatments with existing options.

What the Biggest ASCO Cancer Research Updates Could Mean for Patients

Objective:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

What the Biggest ASCO Cancer Research Updates Could Mean for Patients

Related Content

Associations between CT characteristics of lung cancer lesions and histologic subtypes in lung cancer screening

Implementation Strategies in Cascade Genetic Testing—The Devil Is in the Details

Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer